Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure
- PMID: 17324134
- DOI: 10.1111/j.1440-1681.2007.04585.x
Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure
Abstract
1. In general, cardiac hypertrophy (an increase in heart mass) is a poor prognostic sign. Cardiac enlargement is a characteristic of most forms of heart failure. Cardiac hypertrophy that occurs in athletes (physiological hypertrophy) is a notable exception. 2. Physiological cardiac hypertrophy in response to exercise training differs in its structural and molecular profile to pathological hypertrophy associated with pressure or volume overload in disease. Physiological hypertrophy is characterized by normal organization of cardiac structure and normal or enhanced cardiac function, whereas pathological hypertrophy is commonly associated with upregulation of fetal genes, fibrosis, cardiac dysfunction and increased mortality. 3. It is now clear that several signalling molecules play unique roles in the regulation of pathological and physiological cardiac hypertrophy. 4. The present review discusses the possibility of targeting cardioprotective signalling pathways and genes activated in the athlete's heart to treat or prevent heart failure.
Similar articles
-
Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy.Novartis Found Symp. 2006;274:90-111; discussion 111-7, 152-5, 272-6. Novartis Found Symp. 2006. PMID: 17019808 Review.
-
Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy.Circ Res. 2006 Dec 8;99(12):1411-8. doi: 10.1161/01.RES.0000252345.80198.97. Epub 2006 Nov 9. Circ Res. 2006. PMID: 17095722
-
Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.J Cell Physiol. 2008 Feb;214(2):316-21. doi: 10.1002/jcp.21197. J Cell Physiol. 2008. PMID: 17941081
-
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.Cardiovasc Res. 2011 Feb 1;89(2):265-72. doi: 10.1093/cvr/cvq308. Epub 2010 Sep 28. Cardiovasc Res. 2011. PMID: 20880837 Review.
-
NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure.Cardiovasc Res. 2006 Jul 15;71(2):208-15. doi: 10.1016/j.cardiores.2006.03.016. Epub 2006 Mar 27. Cardiovasc Res. 2006. PMID: 16631149 Review.
Cited by
-
Three-dimensional direct measurement of cardiomyocyte volume, nuclearity, and ploidy in thick histological sections.Sci Rep. 2016 Apr 6;6:23756. doi: 10.1038/srep23756. Sci Rep. 2016. PMID: 27048757 Free PMC article.
-
Progress in Orthotopic Pig Heart Transplantation in Nonhuman Primates.Transpl Int. 2024 Sep 27;37:13607. doi: 10.3389/ti.2024.13607. eCollection 2024. Transpl Int. 2024. PMID: 39399753 Free PMC article. Review.
-
Exercise and cardiac health: physiological and molecular insights.Nat Metab. 2020 Sep;2(9):829-839. doi: 10.1038/s42255-020-0262-1. Epub 2020 Aug 17. Nat Metab. 2020. PMID: 32807982 Review.
-
Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kα signaling in cardiac hypertrophy.J Mol Cell Cardiol. 2012 Jul;53(1):101-12. doi: 10.1016/j.yjmcc.2012.04.012. Epub 2012 May 11. J Mol Cell Cardiol. 2012. PMID: 22580345 Free PMC article.
-
Energy Metabolism in Exercise-Induced Physiologic Cardiac Hypertrophy.Front Pharmacol. 2020 Jul 29;11:1133. doi: 10.3389/fphar.2020.01133. eCollection 2020. Front Pharmacol. 2020. PMID: 32848751 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
